Macular vitelliform lesion in desferrioxamine-related retinopathy
- PMID: 20532952
- PMCID: PMC3690284
- DOI: 10.1007/s10633-010-9236-z
Macular vitelliform lesion in desferrioxamine-related retinopathy
Abstract
To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.
Figures




References
-
- Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf. 1997;17:407–421. - PubMed
-
- Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 1984;91:443–451. - PubMed
-
- Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181–184. - PubMed
-
- Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high-dose subcutaneous Deferoxamine therapy. Can J Ophthalmol. 1985;20:153–156. - PubMed
-
- Cases A, Kelly J, Sabater F, Torras A, Griño MC, Lopez-Pedret J, Revert L. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron. 1990;56:19–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical